• Interpret clinical evidence that supports changes to NVAF care represented in the 2023 ACC/AHA/ACCP/HRS guidelines

• Implement the latest best practices for managing NVAF and providing high-quality care, according to the most recent guidelines from ACC/AHA/ACCP/HRS.

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Primary Author

Alpesh N. Amin, MD, MBA, MACP, MHM, FRCP (Lond), FACC, FHFSA, CPE

Associate Dean for Clinical Transformation
UC Irvine Health
Chief, Division of Hospital Medicine & Palliative Medicine
Department of Medicine
Professor of Medicine, Business, Population & Public Health, Nursing Science, Pharmacy & Pharmaceutical Science, and Biomedical Engineering
University of California, Irvine
Irvine, California

Alpesh N. Amin, MD, MBA, MACP, MHM, FRCP (Lond), FACC, FHFSA, CPE: consultant/advisor/speaker: Alexion, Aseptiscope, AstraZeneca, Bayer, Dexcom, Ferring, Gilead, GlaxoSmithKline, Lilly, Novo Nordisk, Pfizer, Renibus, Reprieve, Salix, Seres, Spero.

Christopher B. Granger, MD

Professor of Medicine and of Nursing
Duke University
Durham, North Carolina

Christopher B. Granger, MD: consultant/advisor/speaker: AbbVie, Abiomed, Alnylam, Anthos, Bayer, Boehringer Ingelheim, Boston Scientific, Bristol Myers Squibb, Cardionomic, Cadrenal, CeleCore Therapeutics, HengRui, Janssen, Medtronic, Merck, Novo Nordisk, Novartis, Pfizer, Philips, REATA, Roche, Veralox; researcher: Alnylam, Boehringer Ingelheim, Bristol Myers Squibb, Janssen, Lilly, Novartis, Pfizer, Philips, Roche.

Andrea Natale, MD, FHRS, FACC, FESC, FAPHRS

Executive Medical Director of the Texas Cardiac Arrhythmia Institute
St David's Medical Center
Austin, Texas
Professor of Medicine
Department of Biomedicine and Prevention
Division of Cardiology
University of Tor Vergata
Rome, Italy
HCA National Medical Director, Cardiology, Cardiac Electrophysiology
Chair of the Cardiac Electrophysiology Operations Council
Cardiac & Vascular Leadership Council
Director, Interventional Electrophysiology, Scripps Clinic
Adjunct Professor of Medicine
Case Western Reserve University
Cleveland, Ohio
Deputy Editor, Europace
Editor in Chief of JAFIB & EP
Austin, Texas

Andrea Natale, MD, FHRS, FACC, FESC, FAPHRS: consultant/advisor/speaker: Abbott, Biosense Webster, Biotronik, Boston Scientific, iRhythm, Medtronic.

The planners and content peer reviewers from Clinical Care Options, LLC do not have any relevant financial relationships to disclose.